Media.Player

Treatment with an Antibody Against VGamma4 T Cells Reduces Rheumatoid Arthritis Symptoms in Mice

Technology Benefits

Targeting a small subset of gamma delta T cells will have fewer side-effects than depleting IL-17 using antibody based technology and won't disrupt the bodies ability to function in other diseases.

Technology Application

Rheumatoid arthritis, cancer, other autoimmune and allergic diseases

Detailed Technology Description

Our scientists have shown in a collagen-induced arthritis murine model:Increased numbers of activated Vgamma4 cells in active diseaseVgamma4 cells were major producers of the inflammatory cytokine, IL-17Administration of a monoclonal antibody targeting Vgamma4 T cells in mice resulted in a 42% decrease in RA histological parameters and a significant decrease in autoantibodies

Supplementary Information

Patent Number: US20080248025A1
Application Number: US200853310A
Inventor: Roark, Christina | O'Brien, Rebecca L. | Born, Willi K.
Priority Date: 27 Mar 2007
Priority Number: US20080248025A1
Application Date: 21 Mar 2008
Publication Date: 9 Oct 2008
IPC Current: A61K0039395 | A61K003817 | A61P003500 | A61P003700 | C12Q000102
US Class: 4241301 | 435029 | 5140011 | 514012
Assignee Applicant: National Jewish Medical and Research Centernver
Title: Gamma Delta T Cells and Methods of Treatment of Interleukin-17 Related Conditions
Usefulness: Gamma Delta T Cells and Methods of Treatment of Interleukin-17 Related Conditions
Summary: The methods are useful for reducing the severity or incidence of a disease or condition associated with the production of IL-17 and identifying an agent useful for the treatment of a disease or condition associated with the production of IL- 17, where the diseases is autoimmune disease is selected from rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, and cancer selected from melanomas, squamous cell carcinomas, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, pancreatic cancers, ovarian cancers, uterine cancers, cervical cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers (including non-small cell lung carcinomas), pancreatic cancers, gastrointestinal cancers (including colorectal cancers), renal cell carcinomas, hematopoietic neoplasias and metastatic cancers (all claimed).
Novelty: Reducing severity or incidence of disease or condition, e.g. autoimmune disease or cancer associated with production of interleukin-17 (IL-17) by deleting, inactivating or inhibiting gamma delta T cells

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

*Abstract

Successful treatment of autoimmune disorders continues to be an unmet challenge. Scientists at National Jewish Health have identified a subset of gamma delta T cells that is active in the pathogenesis of rheumatoid arthritis. These cells produce IL-17, which is associated with inflammatory damage in rheumatoid arthritis, certain cancers, and is a major player in chronic autoimmune diseases. Targeting this small subset of T cells offers a unique way to limit inflammation and treat autoimmune diseases or cancer.

*Principal Investigator

Name: Rebecca O'Brien, Professor

Department: Integrated Department of Immunology

Country/Region

USA